372 related articles for article (PubMed ID: 34405206)
1. Enarodustat to treat anemia in chronic kidney disease.
Fukui K; Tanaka T; Nangaku M
Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
[TBL] [Abstract][Full Text] [Related]
2. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
[TBL] [Abstract][Full Text] [Related]
3. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
[TBL] [Abstract][Full Text] [Related]
4. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Fujikawa R; Nagao Y; Fujioka M; Akizawa T
Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
[TBL] [Abstract][Full Text] [Related]
6. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
7. Enarodustat Treatment for Renal Anemia in Patients With Non-dialysis Chronic Kidney Disease.
Mima A
In Vivo; 2023; 37(2):825-829. PubMed ID: 36881056
[TBL] [Abstract][Full Text] [Related]
8. Enarodustat: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
[TBL] [Abstract][Full Text] [Related]
9. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
[TBL] [Abstract][Full Text] [Related]
10. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Yamada O; Hirakata H
Ther Apher Dial; 2022 Apr; 26(2):345-356. PubMed ID: 34390314
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
[TBL] [Abstract][Full Text] [Related]
15. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
16. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
17. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
18. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
